Literature DB >> 15162841

Risk from inhaled mycotoxins in indoor office and residential environments.

Bruce J Kelman1, Coreen A Robbins, Lonie J Swenson, Bryan D Hardin.   

Abstract

Mycotoxins are known to produce veterinary and human diseases when consumed with contaminated foods. Mycotoxins have also been proposed to cause adverse human health effects after inhalation exposure to mold in indoor residential, school, and office environments. Epidemiologic evidence has been inadequate to establish a causal relationship between indoor mold and nonallergic, toxigenic health effects. In this article, the authors model a maximum possible dose of mycotoxins that could be inhaled in 24 h of continuous exposure to a high concentration of mold spores containing the maximum reported concentration of aflatoxins B1 and B2, satratoxins G and H, fumitremorgens B and C, verruculogen, and trichoverrols A and B. These calculated doses are compared to effects data for the same mycotoxins. None of the maximum doses modeled were sufficiently high to cause any adverse effect. The model illustrates the inefficiency of delivery of mycotoxins via inhalation of mold spores, and suggests that the lack of association between mold exposure and mycotoxicoses in indoor environments is due to a requirement for extremely high airborne spore levels and extended periods of exposure to elicit a response. This model is further evidence that human mycotoxicoses are implausible following inhalation exposure to mycotoxins in mold-contaminated home, school, or office environments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15162841     DOI: 10.1080/10915810490265423

Source DB:  PubMed          Journal:  Int J Toxicol        ISSN: 1091-5818            Impact factor:   2.032


  9 in total

1.  Association of toxic indoor air with multi-organ symptoms in pupils attending a moisture-damaged school in Finland.

Authors:  Saija M Hyvonen; Jouni J Lohi; Leena A Rasanen; Tuula Heinonen; Marika Mannerstrom; Kirsi Vaali; Tamara Tuuminen
Journal:  Am J Clin Exp Immunol       Date:  2020-12-15

2.  The significance of mycotoxins in the framework of assessing workplace related risks.

Authors:  S Mayer; S Engelhart; A Kolk; H Blome
Journal:  Mycotoxin Res       Date:  2008-09       Impact factor: 3.833

3.  Mycotoxins as human carcinogens-the IARC Monographs classification.

Authors:  Vladimir Ostry; Frantisek Malir; Jakub Toman; Yann Grosse
Journal:  Mycotoxin Res       Date:  2016-11-25       Impact factor: 3.833

Review 4.  Mold and Human Health: a Reality Check.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

5.  Biomechanics of conidial dispersal in the toxic mold Stachybotrys chartarum.

Authors:  Kathryn Tucker; Jessica L Stolze; Aaron H Kennedy; Nicholas P Money
Journal:  Fungal Genet Biol       Date:  2006-12-24       Impact factor: 3.495

6.  DNA damage and DNA damage responses in THP-1 monocytes after exposure to spores of either Stachybotrys chartarum or Aspergillus versicolor or to T-2 toxin.

Authors:  Kirsten E Rakkestad; Ida Skaar; Vibeke E Ansteinsson; Anita Solhaug; Jørn A Holme; James J Pestka; Jan T Samuelsen; Hans J Dahlman; Jan K Hongslo; Rune Becher
Journal:  Toxicol Sci       Date:  2010-02-11       Impact factor: 4.849

7.  Mass spectrometry-based strategy for direct detection and quantification of some mycotoxins produced by Stachybotrys and Aspergillus spp. in indoor environments.

Authors:  Erica Bloom; Karol Bal; Eva Nyman; Aime Must; Lennart Larsson
Journal:  Appl Environ Microbiol       Date:  2007-05-04       Impact factor: 4.792

Review 8.  Extrolites of Aspergillus fumigatus and Other Pathogenic Species in Aspergillus Section Fumigati.

Authors:  Jens C Frisvad; Thomas O Larsen
Journal:  Front Microbiol       Date:  2016-01-07       Impact factor: 5.640

9.  Air Disinfection-From Medical Areas to Vehicle.

Authors:  Anna Bukłaha; Anna Wieczorek; Ewelina Kruszewska; Piotr Majewski; Dominika Iwaniuk; Paweł Sacha; Elzbieta Tryniszewska; Piotr Wieczorek
Journal:  Front Public Health       Date:  2022-02-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.